Hologic, Inc. (NASDAQ:HOLX) Shares Acquired by California Public Employees Retirement System

California Public Employees Retirement System increased its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 2.0% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,422,317 shares of the medical equipment provider’s stock after acquiring an additional 27,461 shares during the period. California Public Employees Retirement System’s holdings in Hologic were worth $101,625,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of HOLX. Deseret Mutual Benefit Administrators increased its holdings in Hologic by 42.2% during the 3rd quarter. Deseret Mutual Benefit Administrators now owns 522 shares of the medical equipment provider’s stock worth $36,000 after purchasing an additional 155 shares during the period. Arizona State Retirement System grew its stake in Hologic by 0.3% during the 4th quarter. Arizona State Retirement System now owns 67,319 shares of the medical equipment provider’s stock worth $4,810,000 after buying an additional 172 shares during the last quarter. Allworth Financial LP grew its stake in Hologic by 39.3% during the 4th quarter. Allworth Financial LP now owns 634 shares of the medical equipment provider’s stock worth $45,000 after buying an additional 179 shares during the last quarter. Great Lakes Retirement Inc. grew its stake in Hologic by 1.6% during the 4th quarter. Great Lakes Retirement Inc. now owns 11,859 shares of the medical equipment provider’s stock worth $847,000 after buying an additional 186 shares during the last quarter. Finally, Choate Investment Advisors grew its stake in Hologic by 1.3% during the 3rd quarter. Choate Investment Advisors now owns 15,732 shares of the medical equipment provider’s stock worth $1,092,000 after buying an additional 202 shares during the last quarter. Institutional investors and hedge funds own 94.73% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have weighed in on HOLX shares. William Blair reaffirmed an “outperform” rating on shares of Hologic in a research report on Friday, February 2nd. StockNews.com cut Hologic from a “buy” rating to a “hold” rating in a research report on Friday, March 8th. Needham & Company LLC reaffirmed a “buy” rating and set a $90.00 price objective on shares of Hologic in a research report on Wednesday, April 10th. Raymond James raised their price target on Hologic from $85.00 to $88.00 and gave the company an “outperform” rating in a report on Friday, February 2nd. Finally, Evercore ISI raised their price target on Hologic from $76.00 to $78.00 and gave the company an “in-line” rating in a report on Thursday, April 4th. Six investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $87.00.

Insider Activity

In other news, Director Charles J. Dockendorff sold 1,465 shares of Hologic stock in a transaction on Friday, March 8th. The stock was sold at an average price of $76.21, for a total value of $111,647.65. Following the completion of the sale, the director now owns 1,572 shares of the company’s stock, valued at $119,802.12. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In related news, Director Charles J. Dockendorff sold 1,465 shares of Hologic stock in a transaction on Friday, March 8th. The stock was sold at an average price of $76.21, for a total value of $111,647.65. Following the transaction, the director now owns 1,572 shares in the company, valued at $119,802.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Scott T. Garrett sold 16,441 shares of Hologic stock in a transaction on Thursday, March 14th. The shares were sold at an average price of $75.50, for a total value of $1,241,295.50. Following the completion of the transaction, the director now owns 48,611 shares in the company, valued at approximately $3,670,130.50. The disclosure for this sale can be found here. Insiders sold a total of 32,846 shares of company stock valued at $2,473,443 over the last quarter. Company insiders own 1.75% of the company’s stock.

Hologic Stock Performance

Hologic stock opened at $77.19 on Wednesday. The company has a debt-to-equity ratio of 0.55, a quick ratio of 3.18 and a current ratio of 3.89. The stock has a fifty day moving average of $75.87 and a two-hundred day moving average of $72.69. The company has a market capitalization of $18.12 billion, a price-to-earnings ratio of 36.58, a PEG ratio of 2.58 and a beta of 1.00. Hologic, Inc. has a fifty-two week low of $64.02 and a fifty-two week high of $87.88.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Thursday, February 1st. The medical equipment provider reported $0.98 EPS for the quarter, beating analysts’ consensus estimates of $0.95 by $0.03. The business had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $989.32 million. Hologic had a return on equity of 18.91% and a net margin of 12.98%. The business’s revenue for the quarter was down 5.7% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.07 earnings per share. On average, analysts anticipate that Hologic, Inc. will post 4.01 EPS for the current fiscal year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.